Finnhub•2026-04-21
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific InnovationRPRX — Royalty Pharma PLC
NASDAQ · Pharmaceuticals · Pharmaceuticals
$49.64+29.34%Market cap27.13B
- Latest Close
- $49.64
- 30-Day Move
- +29.3%
- Market Cap
- $27.1B
- Shares Outstanding
- 576,860,000
- P/E Ratio
- 35.19
- P/B Ratio
- 3.44
Analyst consensus: Buy · 16 analysts
NASDAQ:RPRXPharmaceuticals / PharmaceuticalsDelayed public snapshot
Royalty Pharma PLC
A read-only Alphactor snapshot forRoyalty Pharma PLC. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$49.64
30-Day Move
+29.3%
Market Cap
$27.1B
Shares Outstanding
576,860,000
P/E Ratio
35.19
P/B Ratio
3.44
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$49.64
+29.3%last 90 delayed daily bars
Market cap$27.1B
90D High
$50.08
90D Low
$37.83
Avg Volume
3,458,467
What stands out
Net margin is 32.4%, useful for comparing RPRX against peers in Pharmaceuticals.
RPRX is up 29.3% over the last 30 trading days shown on this page.
Latest operating income is $1.6B, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$21.11
Rule of 40
109.8%
Dark Pool Short %
41.4%
Fundamentals snapshot
Latest Close
$49.64
30-Day Move
+29.3%
Market Cap
$27.1B
Shares Outstanding
576,860,000
P/E Ratio
35.19
P/B Ratio
3.44
ROE
11.9%
ROA
3.9%
Operating Margin
65.6%
Net Margin
32.4%
Debt / Equity
1.38
Current Ratio
2.4
Dividend Yield
2.1%
Latest Revenue
$2.4B
Financial statement snapshot
Revenue
$2.4B
Gross Profit
--
Operating Income
$1.6B
Net Income
$771M
Gross Margin
--
Net Margin
3242.0%
Current Ratio
2.40
Debt / Equity
1.38
Valuation snapshot
Fair Value
$21.11
Upside / Downside
-57.5%
Signal
Overvalued
Implied Growth
1.3%
DCF
$50.58
EPV
$6.59
EV/Rev
$6.17
Growth Assumption
2.1%
Discount Rate
8.8%
Terminal Growth
2.0%
Base FCF
$2.5B
Valuation spread
Current Price
$49.64
Composite Fair Value
$21.11
DCF
$50.58
EPV
$6.59
EV/Rev
$6.17
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Quality snapshot
Altman Z
2.25
Grey
Piotroski
5
Moderate (4-6)
Cash Conversion
3.23x
Rule of 40
109.8%
Elite
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $2.2B | $923M | $43M | $2.1B |
| 2023-12-31 | $2.4B | $1.5B | $1.1B | $3.0B |
| 2024-12-31 | $2.3B | $1.3B | $859M | $2.8B |
| 2025-12-31 | $2.4B | $1.6B | $771M | $2.5B |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Finnhub•2026-04-17
Royalty Pharma plc Declares Dividend for the Second Quarter 2026, Payable on June 10, 2026Finnhub•2026-04-17
Royalty Pharma Declares Second Quarter 2026 DividendAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$58M
Buys
0
Sells
54
Buy Value
$0
Sell Value
$58M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | Coyne Terrance P. | Sell | 32,916 | $48.33 |
| 2026-04-01 | Coyne Terrance P. | Sell | 1,875 | $48.33 |
| 2026-03-31 | Bassler Bonnie L | A | 815 | $45.98 |
| 2026-03-23 | Coyne Terrance P. | Sell | 1,875 | $45.53 |
| 2026-03-23 | Coyne Terrance P. | Sell | 32,916 | $45.53 |
| 2026-03-02 | Coyne Terrance P. | Sell | 583 | $47.01 |
| 2026-03-02 | Coyne Terrance P. | Sell | 1,292 | $46.67 |
| 2026-03-02 | Coyne Terrance P. | Sell | 10,429 | $47.01 |
Institutional holders snapshot
Vanguard Group
Filed 2025-08-11
$1.3B
-0.8%
FMR LLC (Fidelity)
Filed 2026-02-17
$1.0B
-6.1%
BlackRock
Filed 2024-05-10
$644M
--
Geode Capital Management
Filed 2025-08-08
$299M
+2.2%
Citadel Advisors
Filed 2026-02-17
$204M
--
Northern Trust
Filed 2026-02-17
$155M
-1.8%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.19
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
16
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.